Envestnet Asset Management Inc. Sells 43,490 Shares of Bruker Corporation $BRKR

Envestnet Asset Management Inc. decreased its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 13.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 269,919 shares of the medical research company’s stock after selling 43,490 shares during the period. Envestnet Asset Management Inc. owned 0.18% of Bruker worth $8,770,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC boosted its position in Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Sculptor Capital LP increased its holdings in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after purchasing an additional 476,363 shares during the period. Brown Advisory Inc. raised its holdings in shares of Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after acquiring an additional 336,026 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its stake in shares of Bruker by 61.6% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after purchasing an additional 796,510 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president owned 128,443 shares in the company, valued at $7,064,365. This trade represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Guggenheim increased their price objective on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, January 26th. TD Cowen dropped their price target on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a report on Wednesday, December 10th. Barclays dropped their price target on Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Wells Fargo & Company upped their target price on shares of Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Bruker has a consensus rating of “Hold” and a consensus target price of $50.38.

Bruker Trading Down 2.5%

Shares of BRKR opened at $38.76 on Friday. The stock has a market capitalization of $5.89 billion, a PE ratio of -258.40, a P/E/G ratio of 2.38 and a beta of 1.19. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The company’s fifty day moving average is $46.29 and its 200 day moving average is $40.45.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the business earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.